Nurix’s Scientist of Cell Screening & Pharmacology, Discovery Technology, Yiqian Li, Ph.D., will discuss Nurix’s accelerated approach to developing novel BTK degraders at the Promega Protein Degradation Symposium today at 5:00 p.m. CDT. Learn more about the symposium here: https://bit.ly/3AwNxPn
Nurix Therapeutics
Biotechnology
San Francisco, CA 16,993 followers
Targeted protein degradation is only the beginning. Blazing a new path in medicine.
Über uns
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
- Website
-
http://www.nurixtx.com
External link for Nurix Therapeutics
- Industrie
- Biotechnology
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- San Francisco, CA
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2012
- Spezialitäten
- research, life sciences, and biotechnology
Standorte
-
Primäre
1700 Owens Street, Suite 205
San Francisco, CA 94158, US
-
8800 Technology Forest Pl
Building 100, Suite 200
The Woodlands, Texas 77381, US
Employees at Nurix Therapeutics
Aktualisierungen
-
Nurix’s Vice President of Discovery Pharmacology, Hao Lu, Ph.D., will discuss Nurix’s novel BTK degraders, NX-5948 and NX-2127 in a presentation at the Promega Protein Degradation Symposium today at 1:00 p.m. CDT. Learn more about the symposium here: https://bit.ly/3AwNxPn
-
Nurix’s Chief Scientific Officer, Gwenn Hansen, Ph.D., will discuss Nurix’s expertise in the discovery and development of Degrader Antibody Conjugates (DACs) in a panel discussion and presentation at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit on Monday, September 10th. Learn more about the summit here: https://lnkd.in/gkpn-Kpa
-
Nurix’s President and CEO, Arthur T. Sands, M.D., Ph.D., will discuss the latest company updates in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9th at 9:30 a.m. ET. Listen to the live or archived discussion here: https://bit.ly/47aMCjF
-
Nurix’s President and CEO, Arthur T. Sands, M.D., Ph.D., will provide a corporate update in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5th at 4:30 p.m. ET. Listen to the live or archived discussion here: https://lnkd.in/gkPQj8pR
-
Nurix’s Associate Director of DEL and Protein Sciences, Marie Malone , Ph.D., will discuss the use of Nurix’s DNA-Encoded Library (DEL) to generate candidate drugs for protein modulation in a presentation at the EFMC-ISMC 2024 Symposium today at 2:50 p.m. CEST. Learn more about the symposium here: https://www.efmc-ismc.org/
-
On #WorldCLLDay, in honor of all patients living with CLL, Nurix affirms its commitment to developing new and innovative medicines to advance patient care. We are developing our novel BTK degrader, NX-5948, for the potential treatment of CLL, the most common form of leukemia in adults. Learn more about our progress here: https://bit.ly/3L7kMKK
-
Nurix’s Senior Scientist of Medicinal Chemistry, Tim Kane, will present a poster on Nurix’s approach to discovering IRAK4 targeted protein degraders at the American Chemical Society Fall meeting taking place August 18-22, 2024. Learn more about this year’s meeting here: https://bit.ly/4d8ew1I #ACSFall2024
-
In the U.S., lung cancers account for 1 in 5 of all cancer deaths. At Nurix, we’re using our targeted protein modulation platform to potentially improve outcomes for those facing a diagnosis of cancer, including lung cancer. https://bit.ly/3L7kMKK #WorldLungCancerDay
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 175.0M